The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâs disease after failure of two other anti-TNF antibodies
P. Michetti
Alimentary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
Andrzej Pilc
View PDFchevron_right
Meta-analysis/Systematic review Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
A. Pilc
Archives of Medical Science, 2013
View PDFchevron_right
Functional Modulation of Crohn’s Disease Myofibroblasts by Anti-Tumor Necrosis Factor Antibodies
David Rampton
Gastroenterology, 2007
View PDFchevron_right
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis
N. Mortensen
Gut, 2006
View PDFchevron_right
Arthritis or vasculitis as presenting symptoms of Crohn’s disease
Ori Segol
Rheumatology International, 2005
View PDFchevron_right
Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations
J.enrique Domínguez-muñoz
European journal of …, 2007
View PDFchevron_right
Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis
Maria de Lourdes Abreu Ferrari
World Journal of Gastroenterology, 2012
View PDFchevron_right
The TNF-α -308 polymorphism may affect the severity of Crohn's disease
Lidiane Bianca Reis
Clinics, 2011
View PDFchevron_right
Clinical prognostic factors for disabling Crohn's disease: A systematic review and meta-analysis
Pedro Pereira Rodrigues
World Journal of Gastroenterology, 2013
View PDFchevron_right
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study
Sofie Joossens
Gastroenterology, 2003
View PDFchevron_right
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
Philippe Van Hootegem
The Lancet, 2008
View PDFchevron_right
Upper gastrointestinal tract phenotype of Crohnʼs disease is associated with early surgery and further hospitalization
Rupert Leong
Inflammatory Bowel Diseases, 2009
View PDFchevron_right
Diagnosis and assessment of Crohns disease: The present and the future
Giovanni Terrosu
Expert Review of Gastroenterology and Hepatology, 2010
View PDFchevron_right
Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease
Guy Aumais
Canadian Journal of Gastroenterology, 2009
View PDFchevron_right
Combination of genetic and quantitative serological immune markers are associated with complicated Crohnʼs disease behavior
Emil Chuang
Inflammatory Bowel Diseases, 2011
View PDFchevron_right
Current Practice of Anti-TNF-α Treatment in Inflammatory Bowel Disease: Results From A National Survey in Sweden
Sven Almer
Journal of Gastroenterology and Hepatology Research, 2014
View PDFchevron_right
Unusual Evolution of a Clinical Case of Crohn’s Disease in a Patient with Multiple Surgeries and Multiple Fistulas
Annibale D'Annibale
Atlas of Ileoscopy, 2013
View PDFchevron_right
A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
David Sachar
Inflammatory Bowel Diseases, 2007
View PDFchevron_right
Fibrotic Strictures and Anti-TNF-α Therapy in Crohn’s Disease
Giovanni Terrosu
Digestion, 2007
View PDFchevron_right
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Hicham El Ossmani
The Lancet Gastroenterology & Hepatology, 2019
View PDFchevron_right
Behaviour of Crohn's disease according to the Vienna classification
David Sachar
Gut, 2002
View PDFchevron_right
Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials
Shekoufeh Nikfar
Biomedecine & Pharmacotherapy, 2007
View PDFchevron_right
Prevention of Post-operative Recurrence in Crohn's Disease
Kim Jong
Intestinal Research, 2008
View PDFchevron_right
The Epidemiology and Phenotype of Crohn’s Disease in the Chinese Population
Rupert Leong
Inflammatory Bowel Diseases, 2004
View PDFchevron_right
An investigation of Crohn's Disease in the Oral Cavity
Maison Ramadan Elchames
2016
View PDFchevron_right
Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease
Christine Breynaert
Alimentary Pharmacology & Therapeutics, 2019
View PDFchevron_right
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Jean-frédéric Colombel, Brian Feagan
Gastroenterology, 2014
View PDFchevron_right
Inflammatory Bowel Disease: the Pathologists Approach to the Clinical Problem
Emil Salmo
Inflammatory Bowel Disease and Familial Adenomatous Polyposis
View PDFchevron_right
Introduction to the Feature Section on “Crohn’s disease activity: MRI assessment and clinical implications”
Francesca Maccioni
Abdominal Imaging, 2012
View PDFchevron_right
Serum protein profile of Crohn's disease treated with infliximab
Gerassimos Mantzaris
Journal of Crohn's and Colitis, 2013
View PDFchevron_right
Crohn’s disease in women
Ivana Plavsic
International Journal of Women's Health, 2013
View PDFchevron_right
What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
Gökhan Kabaçam
The Turkish Journal of Gastroenterology, 2010
View PDFchevron_right
An increase in serum tumour necrosis factor-α during anti-tumour necrosis factor-α therapy for Crohn's disease – A paradox or a predictive index?
Natasza Czepulis
Digestive and Liver Disease, 2016
View PDFchevron_right
Inflammatory Bowel Disease. From Bench to Bedside
Fergus Shanahan
Digestive and Liver Disease, 2004
View PDFchevron_right